Germacrone at 50–100 µM attenuated cisplatin-associated loss of viability in RPTEC/TERT1 cells after 1 h pretreatment followed by 48 h cotreatment with 50 µM cisplatin. Apoptosis measurements supported protection in this renal-cell model. [1]
In PC-3 and 22RV1 prostate cancer cells, the reported 48 h MTT IC50 values were 259 and 396.9 µM, respectively. Germacrone also increased apoptosis. Adding 50 µM chloroquine during the final 6 h of a 48 h exposure to 240 µM germacrone further reduced viability and increased apoptosis; chloroquine alone also affected these endpoints. [2]
Germacrone attenuates cisplatin cytotoxicity in renal tubular cells
Cell-based study · Human RPTEC/TERT1 renal proximal tubular cells [1]
Germacrone pretreatment and cotreatment attenuated the cisplatin-associated loss of MTT viability. Annexin V/PI and Bcl-2 measurements supported reduced apoptosis. Vehicle, cisplatin-alone and germacrone-alone groups were included. This is cell-based protection against a defined chemical insult.
Literature-Reported Treatment Conditions
- Treatment concentration
- 50 and 100 µM germacrone; 50 µM cisplatin
- Exposure duration
- 1 h germacrone pretreatment for combination groups, followed by 48 h cisplatin plus germacrone
- Method
- Cell treatment; MTT, Annexin V-FITC/PI flow cytometry and Bcl-2 immunoblotting
- Vehicle
- Vehicle-treated control reported; vehicle composition not specified
- Co-treatment
- Cisplatin cotreatment; protection is not a germacrone-alone anticancer endpoint.
- Reported limits
- Germacrone purity and treatment vehicle composition are not specified. Figure 1B/C do not separately label the germacrone concentration; no concentration-specific apoptosis magnitude is assigned.
Methods and source locations
Compound reported in the paper: Germacrone; Compound label in the paper: germacrone
Evidence applies to the reported germacrone material and experimental model; no current Adooq lot equivalence or human efficacy is established.
Figure 1A–C and caption; Results: Effect of Germacrone on Cisplatin-Induced Cell Death; Methods: Chemicals, Cell Viability Assay, Cell Apoptosis, Western Blot Analysis
Cisplatin-associated loss of renal-cell viability: MTT; three independent experiments, mean ± S.D. — Figure 1A and caption; first Results subsection
Germacrone reduces intracellular platinum accumulation
Cell-based study · Human RPTEC/TERT1 renal proximal tubular cells [1]
Cells exposed to cisplatin plus germacrone accumulated less platinum than cells exposed to cisplatin alone. The OCT inhibitor tetrapentylammonium (TPeA) served as a mechanistic comparator. This supports an uptake-related component of protection, without establishing a human OCT2 binding constant or transporter exclusivity.
Literature-Reported Treatment Conditions
- Treatment concentration
- 100 µM germacrone plus 100 µM cisplatin; comparator 1 mM TPeA plus 100 µM cisplatin
- Exposure duration
- 1 h germacrone or TPeA pretreatment, followed by 4 h cisplatin cotreatment
- Method
- Cellular platinum determination by flame furnace atomic absorption spectrophotometry
- Vehicle
- Cisplatin-alone comparator; treatment vehicle composition not specified
- Co-treatment
- Cisplatin; separate TPeA comparator
- Reported limits
- No exact percentage reduction is extracted from the plot. The separate OCT uptake assay has unresolved 1-versus-5-min reporting and its potency is withheld.
Methods and source locations
Compound reported in the paper: Germacrone; Compound label in the paper: germacrone
Evidence applies to the reported germacrone material and experimental model; no current Adooq lot equivalence or human efficacy is established.
Figure 2A and caption; Results: Effect of Germacrone on Cellular Accumulation of Cisplatin; Methods: Intracellular Accumulation of Platinum
Intracellular platinum relative to cisplatin alone: Atomic absorption spectrophotometry; three independent experiments; no numerical magnitude or p-value assigned to the Figure 2A comparison — Figure 2A; Results: Effect of Germacrone on Cellular Accumulation of Cisplatin
Germacrone lowers prostate cancer-cell viability
Cell-based study · Human PC-3 and 22RV1 prostate cancer cell lines [2]
After 48 h, germacrone decreased MTT viability with reported IC50 values of 259 µM in PC-3 and 396.9 µM in 22RV1. Annexin V/PI analysis at 240 µM also showed increased apoptosis. These are in vitro assay endpoints.
Literature-Reported Treatment Conditions
- Treatment concentration
- 0, 30, 60, 120, 240 and 480 µM for MTT; 240 µM for the apoptosis comparison
- Exposure duration
- 48 h
- Method
- MTT viability and Annexin V/PI flow cytometry
- Vehicle
- Untreated/0 µM control; treatment solvent not specified
- Co-treatment
- None in the adopted monotherapy comparison
- Reported limits
- Replicate n and treatment vehicle are not specified in the read methods/captions. No uncertainty interval is reported for the IC50 values.
Methods and source locations
Compound reported in the paper: Germacrone; Compound label in the paper: germacrone
Evidence applies to the reported germacrone material and experimental model; no current Adooq lot equivalence or human efficacy is established.
Figure 2 and caption; Figure 3 monotherapy/control panels; Results: Germacrone Decreased the Viability and Induced the Apoptosis; Methods: MTT Assay and Detection of Apoptosis
PC-3 MTT viability after 48 h: MTT, 48 h; value stated in Results, not inferred from curve — Results: Germacrone Decreased the Viability and Induced the Apoptosis; Figure 2
22RV1 MTT viability after 48 h: MTT, 48 h; value stated in Results, not inferred from curve — Results: Germacrone Decreased the Viability and Induced the Apoptosis; Figure 2
Chloroquine enhances germacrone-associated cell death
Cell-based study · Human PC-3 and 22RV1 prostate cancer cells; control, germacrone, chloroquine and combination groups [2]
Adding chloroquine during the final 6 h of germacrone exposure further lowered MTT viability and increased Annexin V/PI apoptosis compared with germacrone alone. Chloroquine alone also affected these endpoints. The interaction is compatible with the paper’s protective-autophagy interpretation, but pharmacological cotreatment does not establish a specific autophagy-dependent mechanism.
Literature-Reported Treatment Conditions
- Treatment concentration
- 240 µM germacrone; 50 µM chloroquine (CQ)
- Exposure duration
- 48 h germacrone exposure; CQ added for the final 6 h
- Method
- MTT viability and Annexin V/PI flow cytometry
- Vehicle
- Untreated control; solvent composition not specified
- Co-treatment
- Chloroquine; all four single/combination/control conditions shown
- Reported limits
- Replicate n and treatment vehicle not specified. Exact numerical apoptosis values are not adopted; representative scatter and group summary bars are not interchangeable.
Methods and source locations
Compound reported in the paper: Germacrone; Compound label in the paper: germacrone
Evidence applies to the reported germacrone material and experimental model; no current Adooq lot equivalence or human efficacy is established.
Figures 3 and 7 with captions; Results: Inhibiting Autophagy Promoted Germacrone-Induced Apoptosis; Methods: Detection of Apoptosis, Western Blotting, Statistical Analysis
Viability and apoptosis with germacrone plus CQ versus germacrone alone: Four-condition comparison; means ± SD per general statistical methods — Figures 3 and 7; Results: Inhibiting Autophagy Promoted Germacrone-Induced Apoptosis